

Richard Raymer

Partner

raymer.richard@dorsey.com

Toronto – 416.367.7388



Richard structures cross-border transactions so Canadian and other foreign companies can expand into the U.S. and access U.S. public and private markets with confidence.

Richard's clients span the pharmaceutical, life sciences, mining, energy, technology, and clean tech sectors, and he regularly guides them through the regulatory and structural complexities that arise when non-U.S. companies seek to raise capital or complete business combinations in the United States.

Richard advises Canadian and other foreign companies on the full range of U.S. securities law matters — from NASDAQ and New York Stock Exchange (NYSE) listings to SEC registration, reporting, and compliance, to public and private debt and equity offerings. Richard also advises U.S. companies on the structuring considerations involved in listing on Canadian stock exchanges, making him a go-to resource for transactions that move in both directions across the border. His work on Rule 144A private placements, registered offerings, and PIPE transactions gives clients a practical understanding of which financing path best fits their timeline, investor base, and disclosure obligations.

Richard has deep experience in cross-border mergers and acquisitions. His experience in cross-border transactions of all kinds allows us him to structure transactions efficiently and to achieve optimum results while minimizing false starts and non-productive efforts

A frequent speaker on U.S. securities law topics, Richard brings a practical, transaction-focused perspective to client counseling. He leads Dorsey & Whitney's Toronto office and has been recognized in Best Lawyers in Canada for Mergers & Acquisitions Law and Securities Law since 2016.

Select Experience

- Represented a pharmaceutical company specializing in the acquisition of legacy and

Education

- New York University School of Law (J.D.)
- McGill University (B.A.)
 - *with great distinction*

Bar Admissions

- New York

orphan products in connection with multiple Rule 144A equity financings, debt financing and bank lending transactions, product acquisitions through merger and asset purchase, regulatory compliance, and various U.S. corporate matters.

- Represented a pharmaceutical company specializing in novel pharmaceutical product development in connection with SEC registration, multiple public and private equity financings including registered offerings and PIPE transactions, SEC reporting and compliance, strategic partnerships, and regulatory compliance.
- Represented a medical device company in connection with multiple cross-border equity financings and U.S. regulatory compliance.
- Represented a pharmaceutical company in connection with multiple U.S. financing transactions and an asset spin-off transaction.

Accolades

- *Lexpert Directory*, 2025-2026
- *Best Lawyers in Canada*®, Mergers & Acquisitions Law and Securities Law, 2016-2026
- *Chambers USA*, Cannabis Law: Corporate/Transactional, 2019

Insights

February 7, 2022

Cannabis Group Of The Year: Dorsey & Whitney